{"id":45420,"date":"2023-06-01T07:35:23","date_gmt":"2023-06-01T07:35:23","guid":{"rendered":"https:\/\/i-base.info\/htb\/?p=45420"},"modified":"2023-06-01T18:46:16","modified_gmt":"2023-06-01T18:46:16","slug":"biomarkers-might-predict-risk-of-hsil-progression-succinyl-coa-and-cobalamin","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/45420","title":{"rendered":"Microbiota biomarkers might predict risk of HSIL progression: succinyl-CoA and cobalamin"},"content":{"rendered":"<div>\n<p class=\"HTBsubhead2articletitle\"><strong>Simon Collins, HIV i-Base<\/strong><\/p>\n<\/div>\n<div>\n<p class=\"HTBBODYtext\"><strong><span lang=\"EN-US\"><img loading=\"lazy\" decoding=\"async\" class=\" wp-image-44826 alignright\" src=\"https:\/\/i-base.info\/htb\/wp-content\/uploads\/2023\/02\/CROI-2023-logo-222x300.png\" alt=\"\" width=\"174\" height=\"232\" \/>An oral presentation by <\/span>Sergio Serrano-Villar from Hospital Ram\u00f3n y Cajal, Madrid looked at whether certain microbiota could predict the risk of progression from HSIL to anal cancer.<\/strong><\/p>\n<\/div>\n<div>\n<p class=\"HTBBODYtext\">The group developed two cohorts of largely MSM in Spain and Italy who were being screened for HSIL <span lang=\"EN-US\">with high-resolution anoscopy and anal biopsies to confirm HSIL<\/span>. One cohort (n=167, with 70 confirmed HSIL) was used to identify potential biomarkers from the <span lang=\"EN-US\">bacterial DNA, proteins, and metabolites from anal cytology samples <\/span>and the second (n=46, with 25 confirmed HSIL) was used to validate any findings.<\/p>\n<\/div>\n<div>\n<p class=\"HTBBODYtext\">HSIL was associated with higher levels of<i> <\/i><span lang=\"EN-US\">Prevotella copri (over-expressing proteins to produce succinyl-CoA and cobalamin) and lower levels of\u00a0Sneathia sanguinegens. <\/span><\/p>\n<\/div>\n<div>\n<p class=\"HTBBODYtext\"><span lang=\"EN-US\">The\u00a0combination of succinyl-CoA and cobalamin improved the sensitivity of testing (compared to anal cytology) from 91.2% to 96.6%, and the specificity from 34.1% to 81.8%. This increased the positive predictive value from 48.1% to 77.8%, and negative predictive value from 85.3% to 97.3%.<\/span><\/p>\n<\/div>\n<div>\n<p class=\"HTBBODYtext\"><span lang=\"EN-US\">The combination of both metabolites improved the classification to 87.7% compared to only 59.9% with anal cytology and the study concluded that these two biomarkers could improve the current strategy for anal cancer screening.<\/span><\/p>\n<\/div>\n<div>\n<h3 class=\"HTBcommenttitle\"><span lang=\"EN-US\">comment<\/span><\/h3>\n<\/div>\n<div>\n<p class=\"HTBBODYtext\"><strong>These preliminary results are interesting and other research groups are investigating changes in metabolic pathways (metabonomics) in cancer detection and diagnosis, so this might become a useful tool in the future.<\/strong><\/p>\n<\/div>\n<div>\n<p class=\"HTBBODYtext\"><strong>However, what works in one specialist centre\u2019s research lab does not often translate to universal applicability. Non-standardised tests need to be validated and will come with additional costs that may outweigh the cost efficiency advantage of improved accuracy of screening.<\/strong><\/p>\n<\/div>\n<div>\n<p class=\"HTBreference-noindent\"><span lang=\"EN-US\">Reference<\/span><\/p>\n<\/div>\n<div>\n<p class=\"HTBreference-noindent\"><span lang=\"EN-US\">Serrano-Villar S et al. Microbiota-derived metabolites are powerful biomarkers for anal cancer prevention. CROI 2023. <\/span><span lang=\"EN-US\">19 \u2013 22 February <\/span><span lang=\"EN-US\">2023. Oral abstract 148.<br \/>\n<\/span><a href=\"https:\/\/www.croiconference.org\/abstract\/microbiota-derived-metabolites-are-powerful-biomarkers-for-anal-cancer-prevention\">https:\/\/www.croiconference.org\/abstract\/microbiota-derived-metabolites-are-powerful-biomarkers-for-anal-cancer-prevention<\/a><\/p>\n<p><em>This report was first posted on 12 May 2023.<\/em><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Simon Collins, HIV i-Base An oral presentation by Sergio Serrano-Villar from Hospital Ram\u00f3n y Cajal, Madrid looked at whether certain microbiota could predict the risk of progression from HSIL to anal cancer. The group developed two cohorts of largely MSM &hellip;<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4,18],"tags":[327],"class_list":["post-45420","post","type-post","status-publish","format-standard","hentry","category-conference-reports","category-cancer-and-hiv","tag-croi-2023"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/45420","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=45420"}],"version-history":[{"count":9,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/45420\/revisions"}],"predecessor-version":[{"id":45563,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/45420\/revisions\/45563"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=45420"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=45420"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=45420"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}